Elena MonzÃ³n Manzano

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6208356/publications.pdf

Version: 2024-02-01

28 papers

138 citations

1478280 6 h-index 1199470 12 g-index

28 all docs

28 docs citations

times ranked

28

218 citing authors

#	Article	IF	CITATIONS
1	Platelet Apoptosis and PAI-1 are Involved in the Pro-Coagulant State of Immune Thrombocytopaenia Patients Treated with Thrombopoietin Receptor Agonists. Thrombosis and Haemostasis, 2019, 119, 645-659.	1.8	31
2	Platelet and immune characteristics of immune thrombocytopaenia patients nonâ€responsive to therapy reveal severe immune dysregulation. British Journal of Haematology, 2020, 189, 943-953.	1.2	27
3	Procoagulant State of Sleep Apnea Depends on Systemic Inflammation and Endothelial Damage. Archivos De Bronconeumologia, 2022, 58, 117-124.	0.4	20
4	Registry of patients with congenital bleeding disorders and COVIDâ€19 in Madrid. Haemophilia, 2020, 26, 773-778.	1.0	18
5	COVIDâ€19 and telemedicine in haemophilia in a patient with severe haemophilia A and orthopaedic surgery. Haemophilia, 2021, 27, e137-e139.	1.0	11
6	Insights into the Procoagulant Profile of Patients with Systemic Lupus Erythematosus without Antiphospholipid Antibodies. Journal of Clinical Medicine, 2020, 9, 3297.	1.0	8
7	The Importance of Platelet Glycoside Residues in the Haemostasis of Patients with Immune Thrombocytopaenia. Journal of Clinical Medicine, 2021, 10, 1661.	1.0	8
8	Pro-apoptotic properties and mitochondrial functionality in platelet-like-particles generated from low Aspirin-incubated Meg-01 cells. Platelets, 2021, 32, 1063-1072.	1.1	4
9	Platelet Protein Glycosylation in Immune Thrombocytopenia. Blood, 2018, 132, 2437-2437.	0.6	2
10	Real Life Experience in Clinical Practice with Recombinant Coagulation FVIII-Fc Fusion Protein. Blood, 2019, 134, 4929-4929.	0.6	2
11	Factors Involved in Maintaining Haemostasis in Patients with Myelodysplastic Syndrome. Thrombosis and Haemostasis, 2018, 47, 734-744.	1.8	1
12	Impact of COVID-19 Pandemic on Patients with Immune Thrombocytopaenia. Medicina (Lithuania), 2021, 57, 219.	0.8	1
13	Prothrombotic State, Platelet Activation and Netosis in Systemic Lupus Erythematosus. Blood, 2019, 134, 1141-1141.	0.6	1
14	Evaluation of Endothelial Damage in Sinusoidal Obstructive Syndrome. Blood, 2016, 128, 5802-5802.	0.6	1
15	Platelet and Immune Characteristics of Patients with Immune Thrombocytopaenia Non Responders to Therapeutic Treatments. Blood, 2019, 134, 1089-1089.	0.6	1
16	Glycomic Characterization of Platelets from Patients with Immune Thrombocytopenia. Blood, 2021, 138, 3158-3158.	0.6	1
17	Thrombin Generation Related to Netosis in Patients with Systemic Lupus Erythematosus. Blood, 2020, 136, 10-11.	0.6	1
18	Procoagulant Profile of Platelets from Immune Thrombocytopenia Patients. Blood, 2016, 128, 1370-1370.	0.6	0

#	Article	IF	CITATIONS
19	Haemostasis in Immune Trombocytopenia Patients Responders to Agonists of Thrombopoietin Receptor. Blood, 2016, 128, 3743-3743.	0.6	O
20	Platelet Apoptosis and PAI-1 Content Are Involved in the Procoagulant Profile of Immune Thrombocytopenia Patients Responders to Agonists of Thrombopoietin Receptor Blood, 2018, 132, 3738-3738.	0.6	0
21	Platelet Dysfunction and Cellular Microparticles May be Involved in the Hipercoagulable State Observed in Obstructive Sleep Apnea Syndrome. Blood, 2018, 132, 5048-5048.	0.6	O
22	Evaluation of the in Vitro Procoagulant Effect of Factor IX Concentrates in Patients on Prophylaxis with Emicizumab. Blood, 2019, 134, 1118-1118.	0.6	0
23	Evaluation of Platelet Function Defects in Patients with Immune Thrombocytopenia. Blood, 2021, 138, 1021-1021.	0.6	O
24	Laboratory Characterization of Unclassified Bleeding Disorders By Non-Conventional Tests. Blood, 2021, 138, 4235-4235.	0.6	O
25	Evaluation of Global Coagulation Tests for Monitoring Bleeding Phenotypes and Response to Treatments in FVII Deficiency. Blood, 2021, 138, 1046-1046.	0.6	O
26	The <i>iin Vitro </i> procoagulant Effects of Standard and Extended Half-Life Recombinant Factor IX Concentrates in Patients on Prophylaxis with Emicizumab. Blood, 2020, 136, 18-19.	0.6	0
27	Fibrin Polymerization Ability Influences Joint Condition in Patients with Severe Haemophilia. Blood, 2020, 136, 17-18.	0.6	O
28	Glycoside Residues on Platelet's Surface Regulate Platelet Function, Apoptosis and Binding of Coagulation Complexes in Patients with Immune Thrombocytopaenia. Blood, 2020, 136, 10-11.	0.6	O